Safety, Effectiveness and Operability of Using the New Tissue Containment System During Laparoscopic Ovarian Cystectomy

Sponsor
China-Japan Friendship Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04406597
Collaborator
(none)
400
2
30

Study Details

Study Description

Brief Summary

The study is designed to evaluate the safety, effectiveness and operability of performing in-bag cystectomy and morcellation with the new tissue containment system during laparoscopic ovarian cystectomy. Premenopausal women, aged 18-45 undergoing laparoscopic cystectomy.

Condition or Disease Intervention/Treatment Phase
  • Device: the New Tissue Containment System
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Safety, Effectiveness and Operability of Using the New Tissue Containment System With Hard Pipes Which Can Assemble With Detachable Trocars Seamlessly for Tissue Removal During Laparoscopic Ovarian Cystectomy
Anticipated Study Start Date :
Jun 10, 2020
Anticipated Primary Completion Date :
Jun 10, 2021
Anticipated Study Completion Date :
Dec 10, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: the New Tissue Containment System group

Using the New Tissue Containment System during Laparoscopic Ovarian Cystectomy

Device: the New Tissue Containment System
Laparoscopic Ovarian Cystectomy using the New Tissue Containment System

No Intervention: Open group

Without any protection system during Laparoscopic Ovarian Cystectomy

Outcome Measures

Primary Outcome Measures

  1. The exposure rate [End of study - approximately two years]

    • Exposure is defined as "disruption of the device (using dye leak testing or water testing) or visible tissue dissemination".

Secondary Outcome Measures

  1. The ovarian reserve function [Three months after the surgery]

    The ovarian reserve function is reflected by the concentration of anti-mullerian hormone(AMH)

  2. Mean procedure time [Within one week after the surgery]

    Mean procedure time will be measured by hour/minutes.

  3. Estimated blood loss during operation [Within one week after the surgery]

    Blood loss during operation will be measured by volume (mL)

  4. Rate of Intra- or post-operative complications [Three months after the surgery]

    Intra or post complications rate (e.g. urinary, intestinal or nerve injury)

  5. The patients' life quality postoperative: questionaire [Three months after the surgery]

    The patients' life quality will be measured by The World Health Organization's Quality of Life Questionnaire-Brief Version(WHOQOL-BREF).The maximum value is 120 and the minimum is 0. The higher score means a better outcome.

  6. The Surgery Task Load Index [Within one week after the surgery]

    The Surgery Task Load Index will be measured by questionaire. The maximum value is 120 and the minimum is 0. The higher score means a worse outcome.

  7. The rate of failure during in-bag cystectomy procedure [End of study - approximately two years]

    Failure is defined as the operator's inability to successfully insert and extract the device.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Premenopausal woman patient age 18-45 years

  • Women with regular period

  • Women with ovarian neoplasm (size: 3-10cm)

  • Laparoscopic surgery required

  • Body mass index 18.5-27.9kg/m2

  • Subject able to comprehend and give informed consent for participation in this study

  • Signed informed consent form

Exclusion Criteria:
  • Patient is not considered suitable for a laparoscopic ovarian cystectomy procedure

  • The ovaries and pelvic cavity are severely adhered, and the tumor ruptures when free

  • Women with Polycystic ovary syndrome

  • Baseline AMH less than 0.5ng / mL

  • Known to have participated in any other clinical trials or hormone therapy within 3 months

  • Women during pregnancy and lactation

  • Women in acute stage infection of reproductive system or other parts

  • Women combined with severe central nervous system, cardiovascular system, liver and kidney, digestive tract, respiratory system, endocrine metabolism (thyroid disease, Cushing syndrome, hyperprolactinemia) and skeletal muscle system and mental disorders contraindicating laparoscopic surgery

  • Women with known or suspected poor compliance who cannot complete the trial

  • Those who can not sign the informed consent

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • China-Japan Friendship Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jing Liang, Vice Director of Obstetrics and Gynecology, China-Japan Friendship Hospital
ClinicalTrials.gov Identifier:
NCT04406597
Other Study ID Numbers:
  • NTCS-LOC
First Posted:
May 28, 2020
Last Update Posted:
May 28, 2020
Last Verified:
May 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 28, 2020